Rituximab biosimilar (Dr Reddy's Laboratories)

利妥昔单抗生物类似药（Dr Reddy's Laboratories）

Report date: 2024/05/17 15:25:45

Base Information

Drug NameRituximab biosimilar (Dr Reddy's Laboratories)
Drug Alias Name利妥昔单抗生物仿制药（Dr Reddy's Laboratories）DRL-rituximabRituximabum (Dr Reddy's Laboratories)DRL_RIRituximab (Dr Reddy's Laboratories) +[10] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsPemphigusMicroscopic PolyangiitisGranulomatosis with Polyangiitis +[7] 
Global Approved IndicationsPemphigusMicroscopic PolyangiitisGranulomatosis with Polyangiitis +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2007/01/01
Country/TerritoryUnited StatesUkraineIndia +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDr.Reddy's Laboratories Ltd
China Registration ClassN/A

Develop Information

Active CompaniesReddy Holding GmbhDr.Reddy's Laboratories Ltd
Inactive CompaniesN/A
Active IndicationsPemphigusMicroscopic PolyangiitisGranulomatosis with Polyangiitis +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC02
Related LinksN/A